The Chemotherapy-Induced Diarrhea (CID) drugs in development market research report provides comprehensive information on the therapeutics under development for Chemotherapy-Induced Diarrhea (CID), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chemotherapy-Induced Diarrhea (CID). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chemotherapy-Induced Diarrhea (CID) and features dormant and discontinued products.
GlobalData tracks eight drugs in development for Chemotherapy-Induced Diarrhea (CID) by seven companies/universities/institutes. The top development phase for Chemotherapy-Induced Diarrhea (CID) is ind/cta filed with three drugs in that stage. The Chemotherapy-Induced Diarrhea (CID) pipeline has eight drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Chemotherapy-Induced Diarrhea (CID) pipeline products market are: Sanarentero, Usynova Pharmaceuticals and Napo Pharmaceuticals.
The key targets in the Chemotherapy-Induced Diarrhea (CID) pipeline products market include Cyclin Dependent Kinase 6, Cyclin Dependent Kinase 4, and Cystic Fibrosis Transmembrane Conductance Regulator.
The key mechanisms of action in the Chemotherapy-Induced Diarrhea (CID) pipeline product include Cystic Fibrosis Transmembrane Conductance Regulator Blocker with one drug in Phase III. The Chemotherapy-Induced Diarrhea (CID) pipeline products include three routes of administration with the top ROA being Oral and four key molecule types in the Chemotherapy-Induced Diarrhea (CID) pipeline products market including Biologic, and Recombinant Protein.
Chemotherapy-Induced Diarrhea (CID) overview
Chemotherapy-induced diarrhea (CID) is a common problem in patients with advanced cancer. The incidence of CID has been reported to be as high as 50-80% of treated patients, especially those treated with a 5-fluorouracil bolus or some combination therapies of irinotecan and fluoropyrimidines. Regardless of the molecular targeted approach of tyrosine kinase inhibitors and antibodies, diarrhea is a common side effect in up to 60% of patients, with up to 10% having severe diarrhea.
For a complete picture of Chemotherapy-Induced Diarrhea (CID)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
